investors.bms.com
Second Quarter 2022
Earnings highlights
Second quarter 2022 results reflect continued in-line product growth, strong momentum across the new product portfolio and continued pipeline progress.
TOTAL NET SALES
GAAP EPS
Non-GAAP EPS**
$11.9B
$0.66*
$1.93*
YoY 2% increase; or 5% When
YoY 18% increase
Adjusted for Foreign Exchange**
*Includes net impact of ($0.14) per share for GAAP and non-GAAP EPS due to Acquired IPRD charges and licensing income. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront
or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.
2022 Guidance1
TOTAL NET SALES
GAAP EPS
Non-GAAP EPS**
$46.0B
$2.71- $3.022
$7.44 – $7.742
1The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward- looking statements as described elsewhere in the document and impact of future Acquired IPRD and charges that may result from the acquisition of Turning Point. Both GAAP and non-GAAP guidance assume current exchange rates.
2GAAP and non-GAAP earnings per share include the net impact of ($0.24) from Acquired IPRD and licensing income incurred year-to- date 2022.
pipeline have given us significant opportunities to drive continued growth, starting with anticipated approval for deucravacitinib in moderate to severe plaque psoriasis and the expected transition of milvexian, our next generation anti-thrombotic, to phase 3 development. With our financial strength and dedicated workforce, we are well positioned to help more patients and drive long-term value for our shareholders.
– Giovanni Caforio, M.D.
Board Chair and Chief Executive Officer
Delivering sustained growth and innovation
In-line Products performance:
$8.7B Revenue
Driven by:
YoY % Increase of 9%
Excluding Foreign Exchange,
YoY % Increase of 13%
New Product Portfolio performance:
Driven by:
$482M in Q2 2022 vs. $225M in Q2 2021
Achieving key milestones
Business Development
BMS maintains a consistent, balanced approach to capital allocation, focused on leveraging strong cash flow generation to invest in internal and external innovation, reducing debt and returning cash to shareholders.
Strong Financial Foundation
Cash and Marketable
Cash Flow
Returned Cash
Securities
from Operating
to Shareholders
Activities
$13.2B
$6.1B (YTD)
$7.3B (YTD)
Environmental, social and governance highlights
As a leading biopharma company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Our evolving Environmental, Social, and Governance (ESG) strategy builds on a legacy of comprehensive and global sustainability efforts. To learn more about our priorities and goals, please visit our latest ESG report.
On June 14, 2022, Deepak L. Bhatt, MD, MPH was elected to BMS’ Board of Directors where he will serve as a member of the Science & Technology Committee. The size of the Board was increased to eleven in connection with the election of Dr. Bhatt.
In July, the company, in collaboration with Disability Solutions, announcedthe launch of the Disability Diversity in Clinical Trials (DDiCT) initiative to improve clinical trial participation of people with disabilities to ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies.
Environment
Key priorities
Embracing environmental stewardship
Commitments
2024 Science-based emissions reduction targets established
2030 100% renewable electricity
2040 Net neutral GHG
100% EV fleet
100% equitable water use
Zero waste to landfill
Social
Key priorities
Promoting product quality & safety
Cultivating diversity, equity & inclusion
Ensuring health equity, patient access & innovation
Commitments
2021 ≥ 25% new clinical trial sites in diverse metro areas
2022 Gender parity at executive level
2X representation for Black/African American & Hispanic/Latino executives
2025 $1B spend with diverse suppliers
Governance
Key priorities
Maintaining highest ethics, integrity & compliance
Upholding Board oversight & accountability
Commitments
Experienced & diverse Board
Shareholder rights
investors.bms.com
© 2022 Bristol-Myers Squibb Company. All Rights Reserved.
Attachments
Disclaimer
Bristol-Myers Squibb Company published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 11:13:09 UTC.

source